Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed

  • Technology appraisal guidance
  • TA715
  • Published: 
Download guidance (PDF)

Update information

August 2021: Recommendation 1.3 updated to clarify when to stop treatment.

ISBN: 978-1-4731-4179-7